Holy_cow
Bluelighter
- Joined
- Nov 29, 2007
- Messages
- 171
I'm taking 600mg of Quetiapine (Seroquel) at 22:00 every night for about 6 month as a sleeping aid. It works very well for this purpose, and unlike with other hypnotics, it remained effective long-term and no tolerance developed. The side effects (rapid heart beat, orthostatic hypotension, clogged up nose) dissapeared over time. I'm getting a long, good sleep and wake up refreshed and without any hangover.
Quetiapine is known to be an antagonist of 5-HT2A receptors (Ki 82nM) but has little effect on 5-HT2C receptors (Ki 1500nM). The hallucinogenic effects of compounds like 2C-E or LSD are thought to be mediated by activation of 5-HT2A receptors. Agonists, but also antagonists, cause desensitation of this receptor (http://www.ncbi.nlm.nih.gov/pubmed/11805206).
I was interested in finding out if a 5-HT2A/C agonist (2C-E) would still cause the typical hallucinogenic/psychedelic effects after chronic pretreatment with Quetiapine.
Thus, today at 13:30 (15.5 hours after the last dose of Quetiapine), I took a dose of 22mg of 2C-E, which is a dose that can be expected to be definitely psychoactive, according to PIHKAL.
It's now 16:00 (T+2:30), and the only effects of the 2C-E I've noticed are a slight, brief gastric discomfort and a slight psychostimulant-like effect with some slight anxiety. There are no hallucinogenic/psychedelic effects, which I have experienced with 2C-E previously, before I commenced Quetiapine treatment.
Conclusion: Chronic pretreatment with the 5-HT2A antagonist Quetiapine anihilates the hallucinogenic/psychedelic effects of the 5-HT2A agonist 2C-E. It is reasonable to assume that this effect will also occur under the treatment with other atypical antipsychotics with 5-HT2A antagonists effects, such as Risperidone, Olanzapine or Clozapine. Psychedelics are without effect under the chronic treatment with atypical, 5-HT2A antagonistic antipsychotics. Furthermore, these findings support the notion that hallucinogenic/psychedelic effects are caused by activation of the 5-HT2A receptor, which gets desensitized not only by agonists, but also by antagonists. The slight residual effects of the non-selective 5-HT agonist 2C-E may be mediated by activation of 5-HT2C and possibly 5-HT3 receptors.
Quetiapine is known to be an antagonist of 5-HT2A receptors (Ki 82nM) but has little effect on 5-HT2C receptors (Ki 1500nM). The hallucinogenic effects of compounds like 2C-E or LSD are thought to be mediated by activation of 5-HT2A receptors. Agonists, but also antagonists, cause desensitation of this receptor (http://www.ncbi.nlm.nih.gov/pubmed/11805206).
I was interested in finding out if a 5-HT2A/C agonist (2C-E) would still cause the typical hallucinogenic/psychedelic effects after chronic pretreatment with Quetiapine.
Thus, today at 13:30 (15.5 hours after the last dose of Quetiapine), I took a dose of 22mg of 2C-E, which is a dose that can be expected to be definitely psychoactive, according to PIHKAL.
It's now 16:00 (T+2:30), and the only effects of the 2C-E I've noticed are a slight, brief gastric discomfort and a slight psychostimulant-like effect with some slight anxiety. There are no hallucinogenic/psychedelic effects, which I have experienced with 2C-E previously, before I commenced Quetiapine treatment.
Conclusion: Chronic pretreatment with the 5-HT2A antagonist Quetiapine anihilates the hallucinogenic/psychedelic effects of the 5-HT2A agonist 2C-E. It is reasonable to assume that this effect will also occur under the treatment with other atypical antipsychotics with 5-HT2A antagonists effects, such as Risperidone, Olanzapine or Clozapine. Psychedelics are without effect under the chronic treatment with atypical, 5-HT2A antagonistic antipsychotics. Furthermore, these findings support the notion that hallucinogenic/psychedelic effects are caused by activation of the 5-HT2A receptor, which gets desensitized not only by agonists, but also by antagonists. The slight residual effects of the non-selective 5-HT agonist 2C-E may be mediated by activation of 5-HT2C and possibly 5-HT3 receptors.
